
CJC-1295 + Ipamorelin (10mg)
no DAC Lyophilised Powder
Concentration
no DAC
Category
Performance & Recovery
Volume Savings
Currently unavailable
Frequently Bought Together
Product Information
CJC-1295 (no DAC) + Ipamorelin (10mg) – Research Grade Blend
CJC-1295 (no DAC) + Ipamorelin (10mg) is available through Aus Peptide Supply with fast domestic shipping to all Australian states and territories.
This pre-blended vial contains two synthetic peptides — CJC-1295 (no DAC) and Ipamorelin — each contributing to growth hormone secretagogue activity through distinct receptor pathways. The blend is manufactured to high purity standards and supported by Certificate of Analysis (COA) documentation from independent third-party laboratories.
Product Specifications
- CJC-1295 (no DAC) content: 6.45mg per vial (as reported on CoA)
- Ipamorelin content: 5.59mg per vial (as reported on CoA)
- Form: Lyophilised powder (pre-blended)
- Verification: Third-party HPLC and mass spectrometry
- Storage: Store at −20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C.
Description
CJC-1295 (no DAC) + Ipamorelin is a laboratory-grade peptide blend intended for analytical, biochemical, and receptor-binding research conducted in controlled environments. CJC-1295 (no DAC) acts via the GHRH receptor, while Ipamorelin acts via the ghrelin receptor — two separate signalling pathways that have been studied in combination in dual-pathway GH secretagogue research models. The lyophilised format supports product stability during storage and transport.
This material is provided strictly for in vitro research use only. It is not for human or veterinary use, nor for any therapeutic, diagnostic, or clinical application.
Research Areas
- Dual-Pathway GH Secretion Studies — Studied as a combination model in which GHRH and ghrelin receptor pathways are activated simultaneously
- GH Pulse Characterisation — Investigated for the magnitude and profile of combined GH secretagogue-induced growth hormone release
- Selectivity Research — Ipamorelin is studied for its selective GH release profile relative to other ghrelin receptor agonists
- Body Composition & Repair Models — Explored in preclinical studies relating to GH/IGF-1 axis effects on lean tissue and recovery mechanisms
Important Use Restrictions
This product is: not for human or veterinary use; not for therapeutic, diagnostic, or clinical applications; not approved as a drug, food, cosmetic, or dietary ingredient; not intended for personal use or consumption.
Compliance Statement
By purchasing this material from Aus Peptide Supply, the buyer confirms they are a qualified professional or authorised representative of a licensed research facility, and will handle the compound in accordance with all applicable regulations and safety guidelines. No claims are made regarding the safety, efficacy, or suitability of this material for any specific research outcome.
⚠ For in vitro research and laboratory use only.


